Surmodics Names Gordon Weber as Senior Vice President of Legal, General Counsel and Secretary

Surmodics, Inc. SRDX, a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today Gordon Weber has joined Surmodics as Senior Vice President of Legal, General Counsel and Secretary effective May 13, 2020.

"Gordon is a seasoned executive with over 30 years of combined business and legal experience, including in the medical device industry," said Gary Maharaj, President and Chief Executive Officer of Surmodics. "He was our legal representative at Faegre & Benson LLP several years ago, so his past experience with Surmodics, along with his firm understanding of the complex laws and regulations affecting the medical device industry, will be immensely beneficial as we pursue our growth objectives."

Prior to joining Surmodics, Weber served as Vice President and General Counsel at CHF Solutions, Inc. a company focused on improving the quality of life for patients suffering from heart failure and related fluid overload conditions. From 2013 until 2017, Weber held the position of Vice President, General Counsel and Corporate Secretary at Vascular Solutions, Inc. and was Associate General Counsel at Smiths Medical from 2010 to 2013. Weber also spent 13 years at Faegre & Benson LLP (now Faegre Drinker), where he was a Partner.

Weber earned his Bachelor of Arts degree from Luther College (Decorah, Iowa) and his Juris Doctor from William Mitchell College of Law (St. Paul, Minnesota).

As Senior Vice President of Legal, General Counsel & Secretary, Weber will be responsible for executive oversight and overall management of the company's legal team while providing counsel and guidance on legal matters. He will be a member of the senior leadership team reporting directly to Maharaj.

About Surmodics, Inc.

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. Surmodics is pursuing highly differentiated medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company's expertise in proprietary surface technologies, along with enhanced device design, development and manufacturing capabilities. The Company mission remains to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics' website is not part of this press release or part of any filings that the company makes with the SEC.

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements. Statements that are not historical or current facts are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including the factors identified under "Risk Factors" in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2019. These reports are available in the Investors section of our website at https://surmodics.gcs-web.com and at the SEC website at www.sec.gov. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them in light of new information or future events.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200514005013/en/